†Score refer to the CMap score. It represents the level of similarity
between transcriptional effects induced by BCG and each of the
compounds.
‡ Validation refers to the presence of any supporting evidence from the
biomedical literature that the predicted BCG mimics have any antiviral
activities. Antiviral means there is evidence that the compound is used
as or has antiviral activity; SARS-CoV-2 means that the compound should
antiviral activity against SARS-CoV-2; Corona viruses means that the
compound showed antiviral activity against corona viruses other than
SARS-CoV-2.
§ COVID-19 CT: there is evidence that the compound is being tested in
clinical trials for COVID-19. There are 12 Studies found for Ruxolitinib
in COVID-19 on clinicaltrials.gov.